Kailera raises $718 million in IPO as shares slide 40%
The obesity-focused biotech priced a large offering but its stock fell sharply in early trading.
The wire
- 01Kailera Therapeutics raised $718 million in its IPO, with shares reported down about 40%.
- 02One of the largest obesity biotech listings, testing investor appetite for GLP-1 challengers.
- 03Post-IPO trading trajectory and pipeline milestones remain to be seen.
From the source
Read at news.google.comKailera Therapeutics targets obesity with GLP-1 drug, raising $718M in IPO despite 40% share drop.